You have 9 free searches left this month | for more free features.

Jakavi

Showing 1 - 25 of 41

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

A PMS of Jakavi® in Steroid-Refractory Graft-versus-Host Disease

Not yet recruiting
  • Graft-versus-Host Disease
  • ruxolitinib
  • (no location specified)
Jan 11, 2023

A Prospective, Two-arm, Non-interventional Study of JAKAVI® in

Active, not recruiting
  • Primary Myelofibrosis
  • +2 more
  • Jakavi
  • Aachen, Germany
    Novartis Investigative Site
Sep 6, 2021

Steroid Refractory GVHD Trial in Taoyuan (Ruxolitinib)

Completed
  • Steroid Refractory GVHD
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital
Dec 15, 2022

Polycythemia Vera Trial (Ruxolitinib)

Available
  • Polycythemia Vera
  • (no location specified)
Mar 7, 2022

Ruxolitinib for Polycythemia Vera in Patients Resistant to or

Completed
  • Polycythemia Vera (PV)
  • Ruxolitinib
  • East Hanover, New Jersey
    Novartis Investigative Site
Jun 29, 2022

Myelofibroses Trial in Saint Louis (Pevonedistat, Ruxolitinib, Peripheral blood draw)

Terminated
  • Myelofibroses
  • Saint Louis, Missouri
    Washington University School of Medicine
Dec 16, 2021

Advanced Cutaneous Squamous Cell Carcinoma Trial in Atlanta, Chicago, New York (Ruxolitinib)

Recruiting
  • Advanced Cutaneous Squamous Cell Carcinoma
  • Atlanta, Georgia
  • +2 more
Jun 28, 2022

A Prospective, Non-interventional Study of JAKAVI® Treatment in

Active, not recruiting
  • Polycythemia Vera
  • Jakavi
  • Reutlingen, Baden Wuerttemberg, Germany
  • +98 more
May 16, 2023

Graft-versus-host-disease, Stem Cell Transplant Complications, Acute Myeloid Leukemia Trial in Moscow, Saint Petersburg

Recruiting
  • Graft-versus-host-disease
  • +3 more
  • Moscow, Russian Federation
  • +1 more
Apr 4, 2022

Severe/Very Severe COVID-19 Illness Trial (Ruxolitinib)

No longer available
  • Severe/Very Severe COVID-19 Illness
  • (no location specified)
Jan 22, 2021

COVID-19, Pneumonia Trial in Toronto (Ruxolitinib)

Terminated
  • COVID-19
  • Pneumonia
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Aug 13, 2021

Polycythemia Vera Trial in London, Oxford (Ruxolitinib, Hydroxycarbamide, Interferon-Alpha)

Recruiting
  • Polycythemia Vera
  • London, United Kingdom
  • +1 more
Nov 29, 2021

COVID-19 Trial (Ruxolitinib)

Withdrawn
  • COVID-19
  • (no location specified)
Mar 3, 2021

Myelofibrosis, Primary Myelofibrosis, Post-PV MF Trial in Canton (TL-895, Ruxolitinib)

Recruiting
  • Myelofibrosis
  • +3 more
  • Birmingham, Alabama
  • +13 more
Jan 10, 2023

Essential Thrombocythemia Trial in Tours (Anagrelide, Ruxolitinib (JAKAVI®), IFNa/ PegIFNa)

Terminated
  • Essential Thrombocythemia
  • Tours, France
    FILO
Jun 28, 2021

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (Biospecimen Collection, Chest

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • Biospecimen Collection
  • +7 more
  • Duarte, California
    City of Hope Medical Center
Nov 9, 2023

Multiple Myeloma Trial in United States (Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone)

Recruiting
  • Multiple Myeloma
  • Ruxolitinib Oral Tablet [Jakafi]
  • +2 more
  • Alhambra, California
  • +12 more
Apr 18, 2022

Bone Marrow Fibrosis Trial in Germany (Allogeneic stem cell transplantation, Ruxolitinib continuous therapy)

Active, not recruiting
  • Bone Marrow Fibrosis
  • Allogeneic stem cell transplantation
  • Ruxolitinib continuous therapy
  • Aachen, Germany
  • +13 more
Aug 20, 2021

Covid-19 Trial in Marseille, Toulon (Anakinra alone (stages 2b/3), Anakinra and Ruxolitinib (overcome stage 3), Standard of

Terminated
  • Covid-19
  • Anakinra alone (stages 2b/3)
  • +2 more
  • Marseille, Bouches-du-Rhône, France
  • +2 more
Dec 11, 2020

Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk

Recruiting
  • Myelofibrosis
  • +2 more
  • Hematopoietic stem cell transplant
  • +2 more
  • Calgary, Alberta, Canada
  • +4 more
Feb 16, 2021

Steroid-Refractory Acute GVHD Trial in Worldwide (T-Guard, Ruxolitinib)

Terminated
  • Steroid-Refractory Acute Graft Versus Host Disease
  • Birmingham, Alabama
  • +47 more
Jan 22, 2023

Myelofibrosis Trial in Worldwide (Ruxolitinib, Siremadlin, Crizanlizumab)

Suspended
  • Myelofibrosis
  • Adelaide, South Australia, Australia
  • +37 more
Aug 18, 2022

Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia Trial

Completed
  • Chronic Phase Chronic Myeloid Leukemia
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Hospital / University Health Network
Oct 29, 2020

Prostate Cancer Trial in Bellinzona (Ruxolitinib 20 MG)

Withdrawn
  • Prostate Cancer
  • Ruxolitinib 20 MG
  • Bellinzona, Switzerland
    Istituto Oncologico della Svizzera Italiana (IOSI)
Mar 24, 2020

Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF) Trial

Available
  • Primary Myelofibrosis (PMF)
  • +2 more
  • (no location specified)
Jan 18, 2022